Compositions including antimicrobial polymer-peptide conjugates and uses thereof

Eduardo Nicolau, San Juan, PR (US); Valerie Ortiz Gómez, San Juan, PR (US)

USPTO: us-12648571 · published 2026-06-09 · patents · A01N 63/50· A01N 25/10· A01P 1/00· A61K 47/545· A61K 47/60· A61L 29/049· A61L 31/041· A61P 31/04

Compositions including antimicrobial polymer-peptide conjugates and uses thereof

Eduardo Nicolau, San Juan, PR (US) , Valerie Ortiz Gómez, San Juan, PR (US) This is my paper

Pith reviewed 2026-06-11 02:31 UTC · model grok-4.3

classification patents A01N 63/50A01N 25/10A01P 1/00A61K 47/545A61K 47/60A61L 29/049A61L 31/041A61P 31/04

keywords antimicrobial peptidePEG conjugatethiol bondpolymer-peptide conjugateamino acid sequenceantimicrobial composition

0 comments

The pith

A polyethylene glycol polymer is conjugated via thiol bond to the peptide sequence ILGPVLGLVSDTLDDVLGILC to form an antimicrobial composition.

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The paper defines a specific conjugate in which a PEG polymer attaches to an antimicrobial peptide containing the sequence ILGPVLGLVSDTLDDVLGILC-COOH through a thiol bond. The linkage can occur at either the N-terminus or the C-terminus of the peptide. The claim centers on this structural composition as the basis for further uses in antimicrobial applications. A sympathetic reader would examine whether this exact linkage and sequence combination provides any practical advantage over existing peptide modifications.

Core claim

The paper claims a peptide conjugate comprising a polyethylene glycol (PEG) polymer conjugated to an antimicrobial peptide (AMP) comprising the amino acid sequence ILGPVLGLVSDTLDDVLGILC-COOH, wherein the AMP is conjugated to the PEG polymer via a thiol bond, optionally at the N-terminus or the C-terminus.

What carries the argument

The thiol bond that links the PEG polymer to the specified antimicrobial peptide sequence.

If this is right

The described conjugate serves as the active component in antimicrobial compositions.
The conjugate may be formulated for therapeutic administration against microbial targets.
Variations in conjugation site (N-terminus or C-terminus) are covered by the same claim.
The composition is positioned for uses involving polymer-peptide hybrids in medical or industrial settings.

Where Pith is reading between the lines

These are editorial extensions of the paper, not claims the author makes directly.

If the conjugate improves peptide stability or circulation time, it could reduce required dosing frequency in potential applications.
The specific sequence might interact differently with bacterial membranes once PEG is attached, altering selectivity.
Further work could test whether the thiol linkage affects the peptide's secondary structure or activity profile.

Load-bearing premise

The given amino acid sequence acts as an antimicrobial peptide and the thiol-linked PEG conjugate forms a novel and useful composition.

What would settle it

Prior art showing the same peptide sequence conjugated to PEG via a thiol bond or experimental results demonstrating that the sequence has no antimicrobial activity.

read the original abstract

1 . A peptide conjugate comprising a polyethylene glycol (PEG) polymer conjugated to an antimicrobial peptide (AMP) comprising the amino acid sequence ILGPVLGLVSDTLDDVLGILC-COOH (SEQ ID NO: 2), or a PEG polymer conjugated to an AMP having an amino acid sequence of SEQ ID NO: 2, wherein the AMP is conjugated to the PEG polymer via a thiol bond, optionally wherein the PEG polymer is conjugated to the N-terminus or the C-terminus of the AMP.

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, simulated authors' rebuttal, and a circularity audit. Tearing a paper down is the easy half of reading it; the pith above is the substance, this is the friction.

Desk Editor's Note private letter to a colleague

This is a patent composition claim for a specific PEG-thiol conjugate to the peptide ILGPVLGLVSDTLDDVLGILC with no data, methods, or validation at all.

read the letter

This patent filing claims a conjugate of polyethylene glycol with the antimicrobial peptide sequence ILGPVLGLVSDTLDDVLGILC-COOH linked via a thiol bond, optionally at either terminus. That is the core of the document: a precise legal definition of one molecular composition for potential uses in devices or agriculture. The sequence itself and the thiol conjugation method are the only concrete elements presented. The claim is written clearly enough to stand as a standalone composition patent. Beyond the sequence definition, the document contains nothing else. No activity data, no stability tests, no comparison to the free peptide or other conjugates, and no description of how the molecule was made or tested. The assumption that the sequence functions as an antimicrobial peptide and that the conjugate adds value is stated but unsupported. This is typical for some early patent filings, but it leaves the reader with no way to assess whether the claim holds up in practice. The document is aimed at IP professionals or groups working on antimicrobial peptides who might want to track the sequence for licensing or follow-on work. It offers no results or methods that a researcher could cite, reproduce, or build on directly. I would not bring it to a reading group or cite it in scientific work. It does not belong in peer review for a journal because it presents no findings, derivations, or evidence for referees to evaluate. If the full patent text includes data that is not in the abstract, that would change the picture, but nothing here indicates it does.

Referee Report

1 major / 0 minor

Summary. The manuscript is a patent composition claim for a peptide conjugate comprising a polyethylene glycol (PEG) polymer conjugated via a thiol bond to an antimicrobial peptide (AMP) with the amino acid sequence ILGPVLGLVSDTLDDVLGILC-COOH (SEQ ID NO: 2), optionally at the N-terminus or C-terminus.

Significance. If the conjugate were shown to retain or enhance antimicrobial activity with improved stability or pharmacokinetics, it could have applications in therapeutic development; however, the complete absence of any data, methods, or validation means no significance can be assigned.

major comments (1)

[Abstract] Abstract: the central claim asserts a specific conjugate composition but provides no experimental data, biological assays, or characterization to establish that SEQ ID NO: 2 functions as an AMP or that the thiol-linked PEG conjugate has any functional properties.

Simulated Author's Rebuttal

1 responses · 1 unresolved

We thank the referee for reviewing our patent composition claim. This document presents a structural claim for a PEG-AMP conjugate rather than a data-driven research manuscript; patent claims define the invention by composition and do not incorporate experimental results.

read point-by-point responses

Referee: [Abstract] Abstract: the central claim asserts a specific conjugate composition but provides no experimental data, biological assays, or characterization to establish that SEQ ID NO: 2 functions as an AMP or that the thiol-linked PEG conjugate has any functional properties.

Authors: The manuscript text consists solely of the composition claim, which states the structural elements (PEG conjugated via thiol bond to the specified sequence, optionally at N- or C-terminus). Patent claims are not required to contain data or assays; any supporting characterization or functional validation would appear in the full specification or examples of the patent application. The claim designates the peptide as an AMP and specifies the conjugation chemistry. No change to the claim language is warranted. revision: no

standing simulated objections not resolved

The manuscript as provided contains no experimental data, methods, or validation, preventing any demonstration of antimicrobial activity or conjugate properties.

Circularity Check

0 steps flagged

No derivation chain or equations; composition claim only

full rationale

The document is a US patent claiming a specific PEG-AMP conjugate composition (SEQ ID NO: 2 linked via thiol). It contains no equations, predictions, fitted parameters, derivations, or self-citations. No load-bearing step exists that could reduce to its own inputs by construction. The claim is a direct compositional statement with no quantitative or logical chain to analyze for circularity.

Axiom & Free-Parameter Ledger

0 free parameters · 0 axioms · 0 invented entities

No mathematical derivations, data fits, or empirical claims are made; the document is a composition claim only. No free parameters, axioms, or invented entities are invoked.

pith-pipeline@v0.9.1-grok · 5673 in / 1103 out tokens · 29485 ms · 2026-06-11T02:31:39.583168+00:00 · methodology

discussion (0)

Lean theorems connected to this paper

Citations machine-checked in the Pith Canon. Every link opens the source theorem in the public Lean library.

IndisputableMonolith.Foundation.RealityFromDistinction reality_from_one_distinction unclear

?

unclear
Relation between the paper passage and the cited Recognition theorem.

A peptide conjugate comprising a polyethylene glycol (PEG) polymer conjugated to an antimicrobial peptide (AMP) comprising the amino acid sequence ILGPVLGLVSDTLDDVLGILC-COOH (SEQ ID NO: 2), wherein the AMP is conjugated to the PEG polymer via a thiol bond
IndisputableMonolith.Cost.FunctionalEquation washburn_uniqueness_aczel unclear

?

unclear
Relation between the paper passage and the cited Recognition theorem.

the AMP is conjugated to the PEG polymer via a thiol bond, optionally wherein the PEG polymer is conjugated to the N-terminus or the C-terminus of the AMP

What do these tags mean?

matches: The paper's claim is directly supported by a theorem in the formal canon.
supports: The theorem supports part of the paper's argument, but the paper may add assumptions or extra steps.
extends: The paper goes beyond the formal theorem; the theorem is a base layer rather than the whole result.
uses: The paper appears to rely on the theorem as machinery.
contradicts: The paper's claim conflicts with a theorem or certificate in the canon.
unclear: Pith found a possible connection, but the passage is too broad, indirect, or ambiguous to say the theorem truly supports the claim.